Manchester Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Manchester Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,989	Closed	-$318K	–	1051
2022 Q2	$318K	Hold	3,989	–	–	0.05%	176
2022 Q1	$420K	Sell	3,989 -159	-4%	-$15.5K	0.06%	175
2021 Q4	$447K	Hold	4,148	–	–	0.06%	175
2021 Q3	$454K	Buy	4,148 +316	+8%	+$32.8K	0.06%	177
2021 Q2	$359K	Buy	3,832 +19	+0.5%	+$1.75K	0.05%	199
2021 Q1	$351K	Sell	3,813 -25	-0.7%	-$2.11K	0.05%	198
2020 Q4	$281K	Buy	3,838 +21	+0.6%	+$1.56K	0.04%	210
2020 Q3	$297K	Buy	+3,817	New	+$263K	0.05%	193
2019 Q2	–	Sell	-1,568	Closed	-$41K	–	682
2019 Q1	$41K	Buy	+1,568	New	+$37.2K	0.01%	430

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Manchester Capital Management's HZNP Position: Q3 2022 in Review

Manchester Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 3,989 shares — an estimated $318K sold.

Manchester Capital Management first reported a position in HZNP in Q1 2019 and held it in 9 quarters. The position peaked at $454K in Q3 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Manchester Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Manchester Capital Management sold 3,989 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $318K.
Manchester Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 9 quarters.
Manchester Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $454K in Q3 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Manchester Capital Management's 13F filing for Q3 2022, filed 8 Nov 2022.